Overview

Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients

Status:
Unknown status

Trial end date:
2016-07-01

Target enrollment:

Participant gender:

Summary

Whether Idarubicin can overcomes multidrug resistant 1 induced chemoresistance with higher induction remission rate than daunorubicin in de novo acute myeloid leukemia patients.Whether induction therapy with IA regimen has a higher remission quality with AML patients than that of DA regimen in high MDR1 expression AML patients.

Details

Lead Sponsor:

Nanfang Hospital of Southern Medical University

Collaborator:

Pfizer

Treatments:

Daunorubicin
Idarubicin